1 report

The company is the first to introduce Full Maglev In 2018, HeartMate ## LVAD was approved for long term use in patients for unviable candidates of heart transplant.

  • Pathology
  • Vaccine
  • World
  • Market Size
  • Cardinal Health, Inc.